Lundbeck sells preclinical drugs to former research exec

The focus on four psychiatric disorders has made Lundbeck sell off two preclinical research projects to a US-based company founded by the former Vice President of the company's US research department. Lundbeck may still profit from the drugs, as there is an option for milestones and royalties.

Two drugs originally developed as possible treatments for psychiatric disorders no longer fit with Lundbeck's business plan, and have therefore been sold. Photo: Lundbeck

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles